Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × saracatinib × Genitourinary × Clear all
NCT00513071 2018-04-19

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01267266 2015-04-01

Saracatinib in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
31 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡